Funding
← Back to your selection

NVIDIA

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026

NVIDIA builds the processors, systems and software used to train and run AI. Its startup relationships combine corporate investment with access to an accelerated-computing ecosystem.

Founders can approach its venture capital arm, NVentures, for investment in technology businesses. NVIDIA also operates Inception, a free programme offering technical training, selected hardware and software pricing benefits, and introductions through its VC Alliance.

Inception has no equity requirement. Applicants need an incorporated company, a working website, an actively involved founder and a use case for NVIDIA technology; a startup can join before it has revenue or starts using NVIDIA products. Membership provides development resources rather than an automatic investment.

Sources
Rounds participated in
3
Confirmed lead rounds
0
All roles disclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$200M
2 disclosed · full round size, not this investor’s share

By stage

Series B1
Series C+1
Undisclosed1

By primary sector

Biotech3

By country

United States2
United Kingdom1

Rounds

3 in this selection
Boltz

Boltz builds biomolecular AI models and software for molecular design and drug-discovery research.

UndisclosedPlanned strategic investment
Participant
Basecamp Research

Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines.

$140MSeries C
Participant
Superluminal Medicines

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

$60MSeries B
Participant